In a proof‐of‐concept study, AZD1981, an oral CRTh2 antagonist, failed to show a significant increase in peak expiratory flow (primary endpoint), but trends towards an improvement in asthma control score were seen in moderate‐to‐severe asthma patients.130. Here, PTGDR2 is linked to asthma.